Survey highlights drugmakers’ CRO needs as demand for services grows
The report, by CRO Worldwide Clinical Trials, shows growing need for early-stage development expertise, with high demand for data quality, efficiency and overall trial management.
Prescription drug market could hit $1.5 trillion by 2021
The QuintilesIMS Institute has released a timely report on the global market for medicines, forecasting a slowdown in drug price increases but overall growth to a massive $1.5 trillion by 2021.
presented by
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Quintiles uses Solution Design Studio in journey to integrate digital tech with clinical trials
In June, Quintiles launched a continuous glucose monitoring service, combining consumer wearable devices and medical device CGM to record glucose readings throughout the day.
What does Disney’s MagicBand have to do with implementing digital health?
Intuituve design and a complex network of partnerships are a couple of things that have helped Disney's MagicBand work.
Two new clinical trial recruitment methods harness the power of IT
A forthcoming app is a sort of Tinder for clinical trial enrollment, so that patients can quickly find clinical trials in their geographic area matching their health interests and needs.
Big Data heavyweights IMS Health and Quintiles to merge in $23B deal
The all-stock transaction brings together companies with a combined enterprise value of upwards of $23 billion and current market capitalization of $17.6 billion.
Validic inks deal with Quintiles to do remote monitoring for clinical trials
The move will help Quintiles improve the frequently costly, lengthy recruitment process for clinical trials.
Quintiles’ study offers view of how pre-screening for personalized cancer treatments would work
How do you match up the appropriate patient with the right drug and implement treatment rapidly? That is a question at the heart of personalized medicine and the focus of a study by Quintiles to develop best practice In a study of patients with colorectal cancer, it’s investigating how pre-profiling and genomic sequencing data, including […]
Quintiles software deal with Allscripts seeks to clear up clinical trial bottlenecks
Quintiles is collaborating with electronic health records firm Allscripts Healthcare Solutions (NASDAQ:MDRX) to develop software to streamline the process of setting up and recruiting for clinical trials in a move that could cut the cost of drug development. The goal is to develop software tools that are designed to significantly reduce some of the bottleneck […]
Quintiles tops investigator recruiting survey but pharmas are ‘dissatisfied outsourcers’
It’s no secret pharmaceutical companies are outsourcing more and more work to clinical research organizations. But when it comes to recruiting doctors to run the studies, they’re not happy at all. In fact, many pharma companies would prefer to do that work themselves. If given the option, nearly half of pharmaceutical companies surveyed by research […]
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Quintiles report: Healthcare payers to get greater drug development role
Pharmaceutical companies and insurers are still figuring out how they’ll work with each other, but a clear majority of both camps surveyed in Quintiles‘ annual New Health Report expect that there will be more collaborations in the future. The survey included more than 1,350 healthcare stakeholders ranging from healthcare payers, executives, patients and investors in […]
What Dennis Gillings told me about Quintiles during a chance encounter
Dennis Gillings doesn’t give many interviews and today, the day his Quintiles successor was announced, he wasn’t available to talk either. I’ve had a few occasions to talk with Gillings and our most recent exchange happened after a life sciences conference in North Carolina a few years ago. By chance, we both left the […]
Why Quintiles hired a CEO with no CRO or pharma experience
Quintiles‘ new CEO Tom Pike brings to the clinical research organization nearly 30 years experience — but none of that time was spent at a CRO or a pharmaceutical company. Pike spent 22 years at management consulting firm Accenture (NYSE:ACN). He was named today the successor to Dennis Gillings, who has led Quintiles since he […]
Quintiles’ names new CEO; Gillings stays on as executive chairman
Quintiles CEO Dennis Gillings is stepping away from the top post of the company he founded and built into the largest clinical research organization in the industry. Tom Pike, a 22-year veteran of management consultant company Accenture, has been appointed Quintiles’ new CEO. Pike will join the Durham, North Carolina-based CRO on April 30. Gillings […]
Quintiles joins Russian investment fund in clinical trials partnership
Quintiles is partnering with a Russian investment fund to create new companies doing clinical trial work in the Russian Federation. No financial terms of the definitive agreement with Russian Venture Company Biofund were disclosed. But the partners said that Russia, the ninth-most populous country in the world, represents an opportunity for clinical trials. “With a […]